A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Authors :: Michael W. Schuster
Reda Bouabdallah
Marie Maerevoet
Miklos Egyed
Josée M. Zijlstra
Federica Cavallo
Nagesh Kalakonda
Ulrich Jaeger
Jatin P. Shah
Catherine Thieblemont
Anita Joshi
Kelly Corona
Xiwen Ma
Olivier Casasnovas
Brian T. Hill
Andre Goy
Joost S.P. Vermaat
Sylvain Choquet
Theodoros P. Vassilakopoulos
Miguel Canales
Juan-Manuel Sancho
Jean-Richard Saint-Martin
Krzysztof Warzocha
Fatima De la Cruz
Fritz Offner
Daniel McCarthy
Sameer Bakhshi
George A Follows
Sourav Mishra
Ronit Gurion
Eric Van Den Neste
Orly Lavee
Source :: Clinical Lymphoma Myeloma & Leukemia, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Publication Year :: 2019
Publisher :: Cancer Media Group, 2019.

Subjects :: Cancer Research
ABCL
business.industry
aggressive B-cell lymphoma
diffuse large B-cell lymphoma
Hematology
XPO1 inhibitor
medicine.disease
Oncology
Phase (matter)
Relapsed refractory
medicine
Cancer research
In patient
business
Diffuse large B-cell lymphoma
selinexor

ISSN :: 21522650
Database :: OpenAIRE
Journal :: Clinical Lymphoma Myeloma & Leukemia, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Accession number :: edsair.doi.dedup.....359c674798b46beca8a0950d8823770b

Tools